Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.
3.
5.

Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.

Metaxas A, Al-Hasani R, Farshim P, Tubby K, Berwick A, Ledent C, Hourani S, Kitchen I, Bailey A.

Neuropharmacology. 2013 Aug;71:228-36. doi: 10.1016/j.neuropharm.2013.03.023.

PMID:
23583933
6.

Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Zambrano CA, Salamander RM, Collins AC, Grady SR, Marks MJ.

J Pharmacol Exp Ther. 2012 Aug;342(2):245-54. doi: 10.1124/jpet.112.192542.

7.
8.

Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine.

Whiteaker P, Jimenez M, McIntosh JM, Collins AC, Marks MJ.

Br J Pharmacol. 2000 Oct;131(4):729-39.

9.

α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration.

Marks MJ, Grady SR, Salminen O, Paley MA, Wageman CR, McIntosh JM, Whiteaker P.

J Neurochem. 2014 Jul;130(2):185-98. doi: 10.1111/jnc.12721.

10.

Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain.

Marks MJ, McClure-Begley TD, Whiteaker P, Salminen O, Brown RW, Cooper J, Collins AC, Lindstrom JM.

J Pharmacol Exp Ther. 2011 Apr;337(1):187-200. doi: 10.1124/jpet.110.178236.

11.

Chronic oral nicotine increases brain [3H]epibatidine binding and responsiveness to antidepressant drugs, but not nicotine, in the mouse forced swim test.

Andreasen JT, Nielsen EO, Redrobe JP.

Psychopharmacology (Berl). 2009 Aug;205(3):517-28. doi: 10.1007/s00213-009-1560-1.

PMID:
19452140
13.

Differential regulation of nicotinic acetylcholine receptors in PC12 cells by nicotine and nerve growth factor.

Avila AM, Dávila-García MI, Ascarrunz VS, Xiao Y, Kellar KJ.

Mol Pharmacol. 2003 Oct;64(4):974-86.

14.

Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells.

Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ.

Mol Pharmacol. 2003 Dec;64(6):1283-94. Erratum in: Mol Pharmacol. 2004 Jul;66(1):197.

16.

(+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors.

Sullivan JP, Decker MW, Brioni JD, Donnelly-Roberts D, Anderson DJ, Bannon AW, Kang CH, Adams P, Piattoni-Kaplan M, Buckley MJ, et al.

J Pharmacol Exp Ther. 1994 Nov;271(2):624-31.

PMID:
7965777
18.

Regulation of nicotinic receptor subtypes following chronic nicotinic agonist exposure in M10 and SH-SY5Y neuroblastoma cells.

Warpman U, Friberg L, Gillespie A, Hellström-Lindahl E, Zhang X, Nordberg A.

J Neurochem. 1998 May;70(5):2028-37.

19.
20.

Nicotinic-agonist stimulated (86)Rb(+) efflux and [(3)H]epibatidine binding of mice differing in beta2 genotype.

Marks MJ, Stitzel JA, Grady SR, Picciotto MR, Changeux JP, Collins AC.

Neuropharmacology. 2000 Oct;39(13):2632-45.

PMID:
11044733
Items per page

Supplemental Content

Support Center